This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
YUM AROC TCAP HYRE ABT CRM BXS BHC CHFC RGA CSCO TBIO UXIN CAH PKD MS HSY GWP SNAP NCMI FOX JCOM HOMB AMC GILD MNLO UTX SYF MDT CYS EXPE ACB GWPH EMHTF JNJ ALV VZ APHQF VNE LMT FB RF.PRB OLED RF.PRA STIM WFC.PRL NFLX WFC.PRJ BAX EHC SKX BAC WFC.PRT ZION OKE.WI WFC.PRR WFC.PRQ WFC.PRP WFC.PRO CYS.PRA CL WFC.PRN CYS.PRB FPBK TCCB OKE WFC.PRY TCCA INTC WFC.PRX WFC.PRW AGS WFC.PRV CBS UL WYNN EVER MA GSK FNSR TCDA UA FFKT NTGN HAS FNKO SBUX CAKE APTV TXN TBQBF XOM ACBFF TWX UAA MS.PRE RF RDI MS.PRF MS.PRG IMAX CNK MS.PRA GTES AMZN TWTR HMNY TWO EBAY BBT ARMO BAC CMA EYEN CRON BV TCC MDLZ CMG PFS MS.PRI BJ GOOGL MS.PRK LVS QCOM FOXA PFE LOVE WFCNP HAL PM HRB WWW GPC PYPL PAGS DLPH MCS PFG TWMJF RDIB AMCX WEED ACN DIS MCD ABT WFC WFC.WS QRVO MJN F SLDB BRY CMCSA K CGC SNPS EMH T MRK CVX FTSV SNE LITE MEDFF PZZA TILE
Amazon.com, Visa Inc., Apple Inc., Alibaba Group Holdings, and Microsoft are the largest five individual stock positions.
UNLNF HSB SCGLF LLOBF ABLZF CSCO UBS.PRDCL TCTZF GE COF-P VOD SCGLY PBR DDAIF AAWW 500180 MSFT NTES RIO WST AXP LEN.B COF-D COF-C COF-F HEI RTNTF ACA FAF BIDU HBCYF HCS.PRB ASML UL VOD UN BHPBF LLY GSK 0005 HDB GNE BHP 8035 TV SSYS VRNT AZN VALE3 MS.PRE FCX MS.PRF MS.PRG SIVB MS.PRA TOELY 6506 6503 VSH PEGA TOELF SMG SLB SMSN VECO PFIZER HCS HEI.A MS.PRI CFRUY MS.PRK RJD SCL SLB PFE RJF SMSD JD COF.PRG HD COF.PRH SSNLF SMFG COF.PRP UBS DG HDFCBANK COF.PRC HSBC COF.PRD ABEV SF.PRA COF.PRF SNN LFUS COST COF MRAAY LECO TORO SNY V PEP VODPF MRK MRAAF LLD5 SU LLD7 LLD6 LLD1 DPZ LLD2 INGR RIO BLT ULVR BECN YASKY SAN SAM AMX MS TSM YASKF INFY UTX BABA NVO JNJ LLDTF NVS BHPLF AZPN BAP LEN WMGI CFRHF RTPPF CLGX BOE AAPL INTC BBVA KBH POOL LLOY ITUB CRARF TTC LLPH ING SAP LLPK MEL LLPJ LLPE JPM LLPD LLPG HSEA HSEB LLPC CRARY 500680 ULSGF SMCAY BCS XOM CTRP COF.WS SEM WMT AMZN TCEHY ASML UNLYF SF BC94 BBD STE BRK.A GOOGL RIO BBL GLE BA EWBC PG NTCT YELP GOOG HRC CHE ASX HSBC.PRA ORCL QRVO PFZ BUD GEC MIELF SFN LYG UMPQ ABB VALE BHP MIELY CVX OCLCF SFB
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
SNWW AST ACHV URGN CDXC OVID AUPH SNWV DRNA AKCA TORC AUP AST.WS OSIR AGN MRK IONS NVS ABBV RMD BMY ABBV
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY
Small-cap stocks continue to put some distance between themselves and their large-cap brethren. Though the Dow Jones Industrial Average and the S&P 500 ended Monday’s trading in the red on lingering fears of a trade war, once again the Russell 2000 Small Cap Index mustered a gain most other market indices couldn’t. Indeed, it’s likely that small-cap stocks are outpacing large-cap alternatives specifically because they’re better shielded from an international trade war.
TTMI RUN PBH USNA AOBC NVDA GSK OSUR JNJ MRK CDXS INTC
One of the most often used arguments in favor of owning Johnson & Johnson (NYSE:JNJ) is its diversity. JNJ stock isn’t just an investment in some of the pharmaceutical industry’s most critical drugs. It’s also an investment in some of the market’s most basic off-the-shelf personal care goods as well as a stake in a medical equipment business most investors simply forget about.
JNJ MRK PFE
There's good and bad news here. The good news is that most sectors rose. In fact, only one sector (Energy) was down and its loss was marginal. But the bad news is that the strongest sectors were defensive. Healthcare rose the most, followed by utilities. The XLP (consumer staples) was the fourth strongest sector.
PM FB PG GILD GOOG CVS V T CL MRK GOOGL JNJ AAPL KO VZ CSCO MSFT INTC PFE BMY MO
Entities affiliated with Google own 5.2% stake in the company. Clients of Wellington Management Company have 6.8% stake as well.
ORPHF ABT MKGAF AMGN CELGZ GILD SURF GOOG TRIL ABT RHHBF ARTH RHHVF MKGAY MRK CELG RHHBY FTSV PDLI
Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. BAN2401, an antibody, seemed to slow the progress of the disease after those in early stages took it for 18 months. It operates by reducing the amount of a protein called beta amyloid. Progress on Alzheimers makes Biogen stock worth at least a look, right?
BIIB MRK JNJ IBB
July 5, 2018: Markets opened higher again Thursday following an offer from the United States to withhold imposing a duty on car imports from the European Union if the EU eliminates its duties. The devil will be in the details. The Fed released the minutes from the last FOMC meeting signaling an end to monetary stimulation but worrying at the same time about the impact of tariffs on business investment and economic growth, both of which the Fed had been sanguine about.
JNJ MRK WBA INTC
RedHill Biopharma (RDHL) announced that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The patents will be in effect until 2029. The company has an important upcoming catalyst related to its RHB-104 candidate. Topline Phase 3 data of RHB-104 trial MAP-US on Crohn's disease expected in early August 2018.
NLNK REDIF ALKS RDHL INCY TLGT OBMP CTIC CTI JAGX SHPG NVTR MRK CELG
Merck & Co. Inc. (NYSE: MRK) shares retreated to start off the week after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted Keytruda for review for a supplemental Biologics License Application (sBLA). This is Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment for metastatic squamous non-small cell lung cancer.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to MRK / Merck & Co., Inc. on message board site Silicon Investor.
as of ET